• 1
    Schneider R, Laxer R. Systemic-onset juvenile idiopathic rheumatoid arthritis [review]. Baillieres Clin Rheumatol 1998; 12: 24571.
  • 2
    Macaubas C, Nguyen K, Deshpande C, Phillips C, Peck A, Lee T, et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 2010; 134: 20616.
  • 3
    Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56: 3793804.
  • 4
    Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, et al. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther 2010; 12: R123.
  • 5
    Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993; 11: 4516.
  • 6
    Ravelli A. Macrophage activation syndrome [review]. Curr Opin Rheumatol 2002; 14: 54852.
  • 7
    Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 96571.
  • 8
    Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 11338.
  • 9
    Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization [review]. Front Biosci 2007; 12: 283648.
  • 10
    Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 730311.
  • 11
    Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization [review]. J Leukoc Biol 2011; 89: 55763.
  • 12
    Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 150515.
  • 13
    Lasiglie D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A, et al. Role of IL-1β in the development of human TH17 cells: lesson from NLPR3 mutated patients. PLoS One 2011; 6: e20014.
  • 14
    Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 195465.
  • 15
    Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 147986.
  • 16
    Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 2012; 160: 98490.e1.
  • 17
    Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 291822.
  • 18
    Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 1993; 15: 928.
  • 19
    De Saint Basile G, Menasche G, Latour S. Inherited defects causing hemophagocytic lymphohistiocytic syndrome [review]. Ann N Y Acad Sci 2011; 1246: 6476.
  • 20
    Schroder K, Hertzog P, Ravasi T, Hume D. Interferon-γ: an overview of signals, mechanisms and functions [review]. J Leukoc Biol 2004; 75: 16389.
  • 21
    Hunter PJ, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum 2010; 62: 896907.
  • 22
    Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 7648.
  • 23
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 3902.
  • 24
    Murray KJ, Luyrink L, Grom AA, Passo MH, Emery H, Witte D, et al. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 1996; 23: 211624.
  • 25
    Schmittgen T, Livak K. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 11018.
  • 26
    Luster AD, Weinshank RL, Feinman R, Ravetch JV. Molecular and biochemical characterization of a novel γ-interferon-inducible protein. J Biol Chem 1988; 263: 1203643.
  • 27
    Wright TM, Farber JM. 5′ regulatory region of a novel cytokine gene mediates selective activation by interferon γ. J Exp Med 1991; 173: 41722.
  • 28
    Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 200921.
  • 29
    Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes [review]. J Leukoc Biol 1997; 61: 24657.
  • 30
    Hu X, Park-Min KH, Ho HH, Ivashkiv LB. IFN-γ-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-γ responses mediated by STAT1. J Immunol 2005; 175: 363747.
  • 31
    Saha B, Prasanna JS, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon γ [review]. Cytokine 2010; 50: 114.
  • 32
    Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597608.
  • 33
    Song M, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 1998; 273: 3505662.
  • 34
    Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of STAT1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998; 95: 1062631.
  • 35
    De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007; 66: 58998.
  • 36
    Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon γ are essential for the disorder. Blood 2004; 104: 73543.
  • 37
    Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-γ-producing lymphocytes and IL-6- and TNF-α-producing macrophages. Blood 2005; 105: 164851.
  • 38
    Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-γ. J Exp Med 1984; 160: 3106.
  • 39
    Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010; 49: 164553.
  • 40
    Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol 2011; 18: 60914.
  • 41
    Bloom BJ. Macrophage activation is a key component in the pathogenesis of systemic juvenile idiopathic arthritis: comment on the article by Bleesing et al [letter]. Arthritis Rheum 2007; 56: 38778.
  • 42
    Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 74754.
  • 43
    Kelchtermans H, Billiau A, Matthys P. How interferon-γ keeps autoimmune diseases in check [review]. Trends Immunol 2008; 29: 47986.
  • 44
    Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases [review]. Immunity 2009; 31: 53950.
  • 45
    Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Schols D, et al. Enhanced autoimmune arthritis in IFN-γ receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol 1999; 163: 350310.
  • 46
    Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J Immunol 1988; 140: 150610.
  • 47
    Page CE, Smale S, Carty SM, Amos N, Lauder SN, Goodfellow RM, et al. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Res Ther 2010; 12: R49.
  • 48
    Hu X, Ho HH, Lou O, Hidaka C, Ivashkiv LB. Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J Immunol 2005; 175: 1318.
  • 49
    Hu Y, Hu X, Boumsell L, Ivashkiv LB. IFN-γ and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways. J Immunol 2008; 180: 805765.